Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Cancer cells can evade immune surveillance through the molecular interactions of immune checkpoint proteins, including programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Since 2011, the FDA-approved antibody drugs ipilimumab (Yervoy(®)), nivolumab (Opdivo(®))...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun Tae, Lee, Sang Hyung, Heo, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470598/
https://www.ncbi.nlm.nih.gov/pubmed/30917623
http://dx.doi.org/10.3390/molecules24061190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470598/
https://www.ncbi.nlm.nih.gov/pubmed/30917623
http://dx.doi.org/10.3390/molecules24061190

Ejemplares similares